Biotech Daily Dose


pharmadown-may21.jpg The following are some of the pharma/biotech stocks that posted the biggest percentage decline on Tuesday.

pharma-032217_17may19.jpg Today's Daily Dose brings you news about Aimmune Therapeutics' upcoming regulatory catalyst; FDA lifting the clinical hold on OPTIC trial; Analyst rating on Outlook Therapeutics and Cellectar Biosciences' $10 million financing.

axonics-may15.jpg Axonics Modulation Technologies Inc. (AXNX) closed at a new high of $31.44 on Tuesday, an impressive 110 percent increase year-to-date. The stock was trading around $14 when we alerted readers to it on January 7, 2019 (Report titled "Axonics Ready To Charge Up?").

solition-may13.jpg Walter Klemp, Executive Chairman of medical device company Soliton Inc. (SOLY), will give a live interview on Yahoo Finance today (May 13) between 9AM - 10AM ET.

drrx-may06.jpg Clinical trial results are major catalysts for biotech/pharma companies. Today, we bring to your attention a biopharma stock, which soared 49% on Friday in the run-up to reporting alcoholic hepatitis trial results - DURECT Corporation (DRRX).

recall-may03.jpg The recall of certain Sartans, which are angiotensin II receptor blockers (ARBs) used to treat high blood pressure, has been making headlines since last year.

exactsciences-may02.jpg Shares of Exact Sciences Corporation (EXAS) touched an all-time high of $101 in intraday trading on Wednesday, and that reflects an impressive 63% gain in just four months.

pharma-030317_01may19.jpg The clinical trial results of a drug company can impact its stock price depending upon the outcome - and more so if it is a small-/mid-cap biopharma stock.

pharma-032018_29apr19.jpg Shares of G1 Therapeutics Inc. (GTHX) rose more than 19% in after-hours on Monday, following positive regulatory update on Trilaciclib, an intravenous CDK4/6 inhibitor in development, to reduce *myelosuppression and enhance immune system function during chemotherapy.

zoetis-april29.jpg Shares of Zoetis Inc. (ZTS) closed at an all-time high of $103.35 on Friday, representing a 22% gain year-to-date.

pharma-030118_23apr19.jpg Shares of InflaRx N.V. (IFRX) have been on a roll since the beginning of this year, hitting new highs.

Follow RTT